Certara (CERT) Company Overview

RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.

Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted EBITDA within Guidance Range of $120 million to $124 million

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.

Detailed Metallurgical test work is ongoing and reaffirms production of DRI grade, 67%+ or better iron concentrate with combined Silica and Alumina below 2.5% Work Programs initiated and DRA Global appointed to deliver NI 43-101 Bankable Feasibility Study by end of Q1 2026 2022 PEA on Mont Sorcier provided an NPV8% of US$1.6 Billion for a 21-year mine life producing 5MT of Iron Concentrate per year (300,000 oz/Au equiv.) generating US$348M per annum in cash flow based upon initial capex of US$574M UKEF and TD Bank have agreed to sponsor 70% of project capital required subject to customary conditions of Export Credit Agency funding (All numbers reported in US dollars) TORONTO, ON / ACCESSWIRE / December 4, 2024 / (TSXV:CERT)(OTCQX:CRDOF) ("Cerrado" or the "Company") is pleased to provide an update on its ongoing work programs to complete a NI 43-101 Bankable Feasibility Study("BFS") by end of Q1 2026 on its High Purity, DRI Grade, +67% iron Mont Sorcier magnetite iron ore project located near Chibougamau, Quebec.

The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024.

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.

Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.